AirSculpt TechnologiesAIRS -1.20%73 EBITDA Margin % is 3.45% as of Mar. 2026, which is 66% below its 10-year median of 10.20. GuruFocus rates AIRS with a GF Score™ of 73/100 and a GF Value™ of $3.93 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 668 Healthcare Providers & Services companies, AirSculpt Technologies ranks worse than 73.35% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
AirSculpt Technologies EBITDA Margin % Related Terms
AirSculpt Technologies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for AirSculpt Technologies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIRS vs CYH, CCRN, AUNA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, AirSculpt Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AirSculpt Technologies EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, AirSculpt Technologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where AirSculpt Technologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AirSculpt Technologies (AIRS) has a EBITDA Margin % of 3.45% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AirSculpt Technologies and its competitors. This is 66% below median its historical median of 10.20. Over the past decade, AirSculpt Technologies' EBITDA Margin % has ranged from 0.61 to 24.97. According to the industry distribution chart, AirSculpt Technologies ranks #490 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 73.4%.
Is AirSculpt Technologies' EBITDA Margin % too high?
AirSculpt Technologies' current EBITDA Margin % of 3.45% is 66% below median its 10-year median of 10.20. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 24.97. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. AirSculpt Technologies' value of 3.45% is 66.2% below this industry median. Based on the distribution chart, AirSculpt Technologies ranks #490 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, AirSculpt Technologies has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AirSculpt Technologies' EBITDA Margin % compare to CYH and CCRN?
According to the Healthcare Providers & Services industry distribution chart, AirSculpt Technologies ranks #490 out of 668 companies for EBITDA Margin %. This places AirSculpt Technologies in the lower half of its industry. The industry median EBITDA Margin % is 10.21. AirSculpt Technologies' value of 3.45% is 66.2% below this benchmark. Historically, AirSculpt Technologies' own EBITDA Margin % has ranged from 0.61 to 24.97 over the past decade. While the company's 10-year median is 10.20 vs. the industry median of 10.21, AirSculpt Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AirSculpt Technologies's current EBITDA Margin % of 3.45% is 66.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AirSculpt Technologies and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AirSculpt Technologies's current EBITDA Margin % is 3.45%, which is 66% below median its own 10-year median of 10.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AirSculpt Technologies stock overvalued right now?
Based on GuruFocus' analysis, AirSculpt Technologies (AIRS) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.93, compared to a current price of $4.55 — trading 15.8% above its estimated fair value. The current EBITDA Margin % is 3.45%, which is 66% below median its 10-year median of 10.20 and 66.2% below the Healthcare Providers & Services industry median of 10.21. AirSculpt Technologies' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For AirSculpt Technologies (AIRS), the current EBITDA Margin % is 3.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AirSculpt Technologies (AIRS) Overvalued in 2026?
Based on GuruFocus' analysis, AirSculpt Technologies stock appears to be overvalued.
The current stock price of $4.55 is trading 15.8% above its estimated GF Value™ of $3.93.
GuruFocus considers AirSculpt Technologies to be Modestly Overvalued.
Key valuation signals for AIRS:
EBITDA Margin %: 3.45% (66% below median its 10-year median of 10.20)
GF Value™: $3.93 vs. price of $4.55 (15.8% above fair value)
Industry Position: 66.2% below the Healthcare Providers & Services median (#490 of 668)
No single metric tells the full story. See the AIRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.
73GF Score
Get the complete analysis for AIRS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIRS has been successfully added to your 
